Plural Nitrogen In The Same Ring (e.g., Barbituates, Creatinine, Etc.) Patents (Class 436/98)
-
Publication number: 20110098306Abstract: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.Type: ApplicationFiled: December 20, 2010Publication date: April 28, 2011Inventors: Pankaj J. Pasricha, Pandu R.R. Gangula
-
Publication number: 20110086428Abstract: The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.Type: ApplicationFiled: July 26, 2010Publication date: April 14, 2011Inventors: Michael E.M. LARSON, Thomas M. Richards
-
Publication number: 20110065137Abstract: Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.Type: ApplicationFiled: August 6, 2010Publication date: March 17, 2011Applicant: Rules-Based Medicine, Inc.Inventors: Samuel T. LaBrie, James P. Mapes, Ralph L. McDade, Dominic Eisinger, Karri L. Ballard, Michael D. Spain
-
Publication number: 20110065136Abstract: Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.Type: ApplicationFiled: August 6, 2010Publication date: March 17, 2011Applicant: Rules-Based Medicine, Inc.Inventors: Samuel T. Labrie, James P. Mapes, Ralph L. McDade, Dominic P. Eisinger, Karri L. Ballard, Michael D. Spain
-
Patent number: 7897402Abstract: Applicants have produced a chromophore and a polymer that are highly sensitive to the presence of various agents, including organophosphates, pesticides, neurotoxins, metal ions, some explosives, and biological toxins. The detection is accomplished by detecting a change in the fluorescence characteristics of the chromophore or polymer when in the presence of the agent to be detected. The chromophore and polymer may be incorporated into sensors of various types, and they are adaptable for potential field use in areas where detection of these types of agents is desired.Type: GrantFiled: April 6, 2010Date of Patent: March 1, 2011Assignee: NDSU-Research FoundationInventors: Johnson Thomas, Philip Boudjouk
-
Publication number: 20110039346Abstract: The present invention relates to a drug detection device for detecting the presence of a date rape drug in a beverage comprising: a straw; and a chemical reagent, where said chemical reagent coats the surface of the straw and changes color upon contact with a date rape drug. In one exemplary embodiment, the drug detection device may be used to test for Gamma Hydoxybutyrate (GHB) or ROHYPNOL® (Flunitrazepam). A stirring straw may be used as a component of the drug detection device as opposing to a conventional straw. The present invention also includes a method of date rape drug detection comprising the steps of: coating a stirring device with a chemical reagent; inserting the stirring device in a beverage; and observing the stirring device to determine an indication of the presence of a date rape drug.Type: ApplicationFiled: August 13, 2009Publication date: February 17, 2011Inventors: Michael BRADLEY, Anthony LEWIS
-
Publication number: 20110027897Abstract: The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.Type: ApplicationFiled: August 28, 2008Publication date: February 3, 2011Inventors: Chaitan Khosla, Michael Bethune
-
Patent number: 7879617Abstract: A method for measuring the concentration of creatinine includes the steps of: (A) mixing a sample containing creatinine with a creatinine quantitative reagent including 1-methoxy-5-methylphenazinium in the absence of picric acid and any enzyme responsive to creatinine, to cause the creatinine to reduce the 1-methoxy-5-methylphenazinium; (B) electrochemically or optically measuring the amount of the 1-methoxy-5-methylphenazinium reduced in the step (A); and (C) determining the concentration of the creatinine contained in the sample from the amount of the reduced 1-methoxy-5-methylphenazinium measured in the step (B).Type: GrantFiled: January 6, 2010Date of Patent: February 1, 2011Assignee: Panasonic CorporationInventors: Takahiro Nakaminami, Hiroaki Tachibana, Masato Suzuki
-
Publication number: 20110003395Abstract: Labeling reagents, sets of labeling reagents, and labeling techniques are provided for the relative quantitation, absolute quantitation, or both, of ketone or aldehyde compounds including, but not limited to, analytes comprising steroids or ketosteroids. The analytes can be medical or pharmaceutical compounds in biological samples. Methods for labeling, analyzing, and quantifying ketone or aldehyde compounds are also disclosed as are methods that also use mass spectrometry.Type: ApplicationFiled: June 1, 2010Publication date: January 6, 2011Applicant: DH TECHNOLOGIES DEVELOPMENT PTE. LTD.Inventors: Subhakar DEY, Sasi PILLAI, Brian L. WILLIAMSON, Subhasish PURKAYASTHA, Michal Weinstock
-
Publication number: 20100303832Abstract: The invention relates to genes, gene polymorphisms, and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a patient which facilitate assessment of risk for developing such diseases.Type: ApplicationFiled: November 3, 2008Publication date: December 2, 2010Inventor: Gregory S. Hageman
-
Publication number: 20100298649Abstract: A system and method for assessment of a brain status of a subject are disclosed. The brain status comprises a brain disease induced brain dysfunction. An occurrence and/or stage of the brain disease induced brain dysfunction in the subject is determined. The system comprises an apparatus that is adapted to determine the occurrence and/or stage of the brain disease induced brain dysfunction in the subject from random speech of the subject.Type: ApplicationFiled: November 3, 2008Publication date: November 25, 2010Inventors: Siegbert Warkentin, Catarina Erikson
-
Publication number: 20100297638Abstract: The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore.Type: ApplicationFiled: October 6, 2008Publication date: November 25, 2010Applicant: ISIS INNOVATION LIMITEDInventors: John Hagan Bayley, Haichen Wu, Giovanni Maglia, Yann Astier
-
Publication number: 20100291113Abstract: Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA. In some embodiments, the method comprises restricting folate intake by the patient. Methods of monitoring cancer therapy are provided as well as kits for treating cancer and kits for monitoring cancer therapy.Type: ApplicationFiled: October 3, 2008Publication date: November 18, 2010Applicant: Cornell UniversityInventor: Neil H. Bander
-
Patent number: 7820449Abstract: The present invention provides a novel test piece for creatinine measurement. The test piece includes a compound expressed by the following formula (1), a metal that forms a colored complex with the compound, and a buffer agent in a porous material. The amount of creatinine is determined by optically measuring a colored complex of the compound and the metal and evaluating the degree of inhibition of the colored complex formation by creatinine. In the formula (1), R1 represents H, SO3X, or COOX. R4 and R6 represent OH, SO3X, or COOX and may be either the same or different. R2, R3, R5, and R7 represent H, OH, Cl, Br, I, NO2, NO, or CH3 and may be either the same or different. Xs in the R1, R4, and R6 represent H, Na, K, or NH4 and may be either the same or different.Type: GrantFiled: October 15, 2003Date of Patent: October 26, 2010Assignee: ARKRAY, Inc.Inventor: Hideko Kosaka
-
Publication number: 20100267068Abstract: Process for determination of a drug or medicament or their metabolites in a (body) fluid or an extract of (body) tissue or (body) sample comprising the steps: (i) optionally treatment of the fluid or sample extract with at least one enzyme, (ii) contacting at least a first part of the fluid or extract with at least one first solid phase able to adsorb or absorb organic compounds out of the fluid or extract, and/or (iii) contacting at least a second part of the fluid or extract with at least one second phase, able to extract or adsorb organic compounds out of the fluid or extract, and/or (iv) optionally contacting at least a third part of the fluid or extract with a liquid phase able to extract organic compounds out of the fluid or extract, and/or (v) desorbing the compound(s) bound to the first solid phase by applying heat to the solid phase and/or by solvent extraction, optionally followed by evaporating the solvent at least partially, (vi) optionally extracting or desorbing the compound(s) contained in or bType: ApplicationFiled: July 11, 2008Publication date: October 21, 2010Inventors: Douwe De Boer, Bert Kip, Ynze Mengerink, John Mommers, Roland Peters, Nicolle Reumkens
-
Publication number: 20100267004Abstract: A method for labeling biological molecules and synthetic molecules that contain a geminal diol, such as RNA, carbohydrates or glycoproteins, using a periodate sequestering agent is provided. Compositions and kits for use in the labeling method are also provided.Type: ApplicationFiled: October 31, 2008Publication date: October 21, 2010Applicant: BIOVENTURES, INC.Inventors: Elliott P. Dawson, Kristie E. Womble
-
Patent number: 7816145Abstract: A method for measuring a concentration of creatinine includes the steps of: (A) mixing a sample containing creatinine with a creatinine quantitative reagent containing a metal complex of at least one of hexacyanoferrate and hexacyanoruthenate in the absence of picric acid and any enzyme responsive to creatinine, to cause the creatinine to reduce the metal complex; (B) electrochemically or optically measuring the amount of the metal complex reduced in the step (A); and (C) determining the concentration of the creatinine contained in the sample from the amount of the reduced metal complex measured in the step (B).Type: GrantFiled: March 4, 2010Date of Patent: October 19, 2010Assignee: Panasonic CorporationInventors: Takahiro Nakaminami, Kouji Kashiwada, Atsushi Fukunaga
-
Publication number: 20100260747Abstract: Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.Type: ApplicationFiled: April 9, 2010Publication date: October 14, 2010Applicant: BAYLOR RESEARCH INSTITUTEInventors: Raphael Schiffmann, Teodoro G. Bottiglieri, Erland Arning, David F. Moore
-
Publication number: 20100221338Abstract: Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed.Type: ApplicationFiled: January 28, 2010Publication date: September 2, 2010Applicant: SEPRACOR INC.Inventors: Richard Hsia, Cai Gu Huang, Konstantinos E. Saranteas, Tushar K. Misra, Philip J. Bonasia, JR.
-
Patent number: 7785895Abstract: The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.Type: GrantFiled: August 3, 2009Date of Patent: August 31, 2010Assignee: Marshfield ClinicInventors: Michael E. M. Larson, Thomas M. Richards
-
Publication number: 20100209507Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.Type: ApplicationFiled: April 27, 2010Publication date: August 19, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Henry C. Lin, Mark Pimentel
-
Publication number: 20100203650Abstract: The invention provides biomolecule binding ligands, collections of biomolecule binding ligands, and their use in the purification of biological mixtures and in the identification of ligands having an affinity for a substance.Type: ApplicationFiled: June 27, 2008Publication date: August 12, 2010Applicant: CAMBRIDGE ENTERPRISE LIMITEDInventors: Christopher Robin Lowe, Abid Hussain, Michael Luis Mimmack, Jonathan Michael Haigh
-
Publication number: 20100204163Abstract: The invention relates to derivatives and metabolites of ambrisentan, including compounds of general Formula (I) or salts, hydrates, solvates, racemates, or optical isomers thereof, wherein R1 is —H or —OCH3; R2 is —H, lower alkyl (e.g. C1-C4 alkyl) or glycosidyl; and R3 and R4 are independently —CH3, —C(O)H or —CH2OR6, wherein R6 is —H or a hydrocarbyl group having 1 to 20 carbon atoms. In some embodiments, compounds of Formula (I) exhibit selective affinity for ETA receptors and serve as endothelin receptor antagonists. In some embodiments, the compounds correspond to metabolites of ambrisentan produced by the enzymatic action of cytochrome P450 or uridine diphosphate glucuronosyl transferase enzymes, for example as elucidated in pre-clinical or clinical studies.Type: ApplicationFiled: July 31, 2008Publication date: August 12, 2010Applicant: Gilead Colorado, Inc.Inventors: Lawrence S. Melvin, JR., Martina Ullrich, Hans-Guenther Hege, Jürgen Weymann
-
Publication number: 20100178705Abstract: An apparatus, system and method of detecting contaminants, such as melamine, in at least one ingestible item. The apparatus, system and method may include a disposable notched probe having therein at least one send and one receive fiber optic, or electrical, or heat source, and a reactant associated with said disposable notched probe, wherein a reaction of the reactant with at least a portion of the ingestible item indicates, to the consumer user, a presence of a contaminant.Type: ApplicationFiled: December 8, 2009Publication date: July 15, 2010Inventors: Morton Greene, Edward Yokley
-
Publication number: 20100173306Abstract: The present invention provides a method for specifically detecting a G-quadruplex, and the like. The method for detecting a G-quadruplex of the present invention is characterized by including the steps of: (a) preparing a solution including an anionic planar phthalocyanine; (b) mixing the solution including an anionic planar phthalocyanine with the sample solution; and (c) measuring the absorbance at 640 to 740 nm of a liquid mixture obtained following the step (b).Type: ApplicationFiled: December 30, 2009Publication date: July 8, 2010Applicant: PANASONIC CORPORATIONInventors: Hidenobu YAKU, Daisuke Miyoshi
-
Publication number: 20100173346Abstract: Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.Type: ApplicationFiled: March 24, 2008Publication date: July 8, 2010Applicant: BG MEDICINE, INC.Inventors: Aram Adourian, Doris Damian, Amir Handzel
-
Publication number: 20100047916Abstract: Methods and devices for detecting the presence of a NO forming material (e.g., a material that can form, or is, a nitrogen monoxide molecule) are disclosed based on detection of fluorescence exhibited by NO molecules in a first vibrationally excited state of a ground electronic state. Such excited NO molecules can be formed, for example, when small amounts of explosives are photodissociated. By inducing fluorescence of the material, a distinct signature of the explosive can be detected. Such techniques can be performed quickly and with a significant standoff distance, which can add to the invention's utility. In another aspection of the invention, methods and apparatus for generating electromagnetic radiation are disclosed. Such methods and apparatus can be used in conjunction with any detection method disclosed herein.Type: ApplicationFiled: July 10, 2009Publication date: February 25, 2010Applicant: Massachusetts Institute Of TechnologyInventors: Mordechai Rothschild, Charles M. Wynn, John J. Zayhowski, Roderick R. Kunz
-
Publication number: 20100035354Abstract: The present invention provides a processes for preparing 5-Azacytidine, and intermediates thereof. The present invention further provides an analytical method for determining the purity of 5-Azacytidine in a sample.Type: ApplicationFiled: August 6, 2009Publication date: February 11, 2010Inventors: Ettore Bigatti, Giovanna Lux, Maurizio Paiocchi
-
MICROWAVE TRIGGER METAL-ENHANCED CHEMILUMINESCENCE (MT MEC) AND SPATIAL AND TEMPORAL CONTROL OF SAME
Publication number: 20100003695Abstract: The present invention relates to a method of imaging structures and features using plasmonic emissions from metallic surfaces caused by chemiluminescence based chemical and biological reactions wherein imaging of the reactions is enhanced by the use of microwave energy and further enhanced by using metallic geometric structures for spatially and temporally controlling the biological and chemical reactions.Type: ApplicationFiled: February 25, 2008Publication date: January 7, 2010Applicant: UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTEInventors: Chris D. Geddes, Michael Previte -
Publication number: 20090318369Abstract: The present invention provides various biomarkers of Alzheimer's Disease (AD). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of AD, methods of determining predisposition to AD, methods of monitoring progression/regression of AD, methods of assessing efficacy of compositions for treating AD, methods of screening compositions for activity in modulating biomarkers of AD, methods of treating AD, as well as other methods based on biomarkers of AD.Type: ApplicationFiled: August 15, 2008Publication date: December 24, 2009Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20090318556Abstract: Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, ?-thymidine, taurine, xanthine, xanthosine, 2?-deoxyuridine, 2?-deoxycytidine, 2?-deoxyxanthosine, or any salt, ion, or combination thereof. Also disclosed are methods for determining gamma radiation exposure by an animal or human, which include the step of measuring the amount of one or more biomarkers specific to gamma radiation in the biological fluid and correlating the amount of said biomarkers to the amount of gamma radiation exposure by the animal or human. Systems for determining gamma radiation exposure by an animal or human and methods of treating an animal or human for gamma radiation exposure are also disclosed.Type: ApplicationFiled: May 15, 2008Publication date: December 24, 2009Inventors: Jeffrey R. Idle, Frank J. Gonzalez, John B. Tyburski, Kristopher W. Krausz, Andrew David Patterson
-
Publication number: 20090311795Abstract: Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of transporters for neurotransmitters, and or neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems. The methods may also include determining a urinary neurotransmitter phase response to a change in dosing of supplemental amino acid precursors of the serotonin and catecholamine neurotransmitters to optimally treat neurotransmitter transporters, neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems.Type: ApplicationFiled: June 12, 2009Publication date: December 17, 2009Inventor: Martin C. Hinz
-
Patent number: 7629461Abstract: The present invention provides an isolated N-formyl valacyclovir, its preparation and its use as a reference marker and/or reference standard.Type: GrantFiled: September 6, 2005Date of Patent: December 8, 2009Assignee: Teva Pharmaceutical Industries LtdInventors: Amihai Eisenstadt, Michael Pesachovich
-
Publication number: 20090291996Abstract: The present invention provides Caspofungin and salts thereof substantially free of Caspofungin C0 and salts thereof. The present invention also provides processes for the preparation of said Caspofungin and salts thereof and processes for the determination of the amount of Caspofungin C0 and salts thereof present in Caspofungin and salts thereof. The present invention further provides pharmaceutical compositions comprising said Caspofungin and salts thereof.Type: ApplicationFiled: May 21, 2009Publication date: November 26, 2009Inventors: Ferenc Korodi, Piroska Kovacs, Andrea Csorvasi, Gabor Nagy
-
Publication number: 20090291468Abstract: The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.Type: ApplicationFiled: August 3, 2009Publication date: November 26, 2009Inventors: Michael E.M. Larson, Thomas M. Richards
-
Publication number: 20090286322Abstract: Disclosed is a testing apparatus for detecting the presence of harmful substances in a fluid. The testing apparatus includes a base member and a flap member removably attached to the base member. Further, the testing apparatus includes at least one testing stick enclosed within the base member. The at least one testing stick includes an elongated member and a chemical reagent disposed on the elongated member. The chemical reagent is capable of reacting with the harmful substances. Such a reaction of the chemical agent with the harmful substances results in a change in a color of the chemical reagent indicating the presence of the harmful substances in the fluid. Further disclosed is a method for detecting the presence of the harmful substances in the fluid using the testing apparatus.Type: ApplicationFiled: May 16, 2008Publication date: November 19, 2009Inventor: Donna Dancer
-
Publication number: 20090215185Abstract: Analytical chemical reagents termed non-signal imidazoles and a method for their use that provide a host of advantages for analysis of phosphomonoesters are described. The method and compounds of the invention provide a host of advantages for the analysis of phosphomonoester-containing compounds, namely characteristic, multi-analyte detection with high sensitivity and specificity of known and unknown phosphomonoester-compounds simultaneously.Type: ApplicationFiled: June 21, 2006Publication date: August 27, 2009Inventors: Poguang Wang, Guodong Li, Roger W. Giese
-
Publication number: 20090186419Abstract: The present invention relates to articles and methods involving luminescent films which may be useful in various applications. Luminescent films of the present invention may comprise a layer of metal oxide nanoparticles and, in some cases, may interact with an analyte to generate a detectable signal, whereby the presence and/or amount of analyte can be determined. In some embodiments, fluorescence resonance energy transfer (FRET) may occur between the luminescent film and the analyte. Such articles and methods may be useful in, for example, biological assays or in sensors.Type: ApplicationFiled: January 20, 2006Publication date: July 23, 2009Applicant: Agency for Science ,Technology and ResearchInventors: Jackie Y. Ying, Hsiao-Hua Yu, Emril Mohamed Ali
-
Publication number: 20090157328Abstract: Methods and kits of the invention are useful for calculating 24-hour excretion of sodium without the need to collect urine for 24 hours.Type: ApplicationFiled: December 12, 2008Publication date: June 18, 2009Applicant: Cornell UniversityInventors: Samuel J. Mann, Linda M. Gerber
-
Patent number: 7524681Abstract: The present invention relates to a method for determining the condition of a biological fluid by recording the IR spectrum of a sample of the biological fluid. To this end, the biological fluid can be examined in its native form. The method of the invention is usable, for example, for detecting pathological conditions in organisms.Type: GrantFiled: January 22, 2002Date of Patent: April 28, 2009Inventors: Andreas Wolf, Ralf Masuch, Robert Seidel
-
Publication number: 20080317835Abstract: Assays are preformed to determine nutrient deficiency levels in an individual to address the deficiencies and improve health and longevity. Nutraceutical and cosmeceutical products containing nanoencapsulated active ingredients are provided, in addition to dietary, exercise, sleep, and other lifestyle recommendations.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Inventors: Nazli Azimi, Mohammad Saeed Kharazmi
-
Publication number: 20080261317Abstract: The disclosed methods address the identification of myocardial ischemia and myocardial infarction using metabolomics, as well as the identification of metabolic products whose differential expression over time is indicative of myocardial ischemia and/or myocardial infarction.Type: ApplicationFiled: September 6, 2005Publication date: October 23, 2008Inventors: Michael A. Fifer, Marc S. Sabatine, Robert Gerszten
-
Publication number: 20080176852Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.Type: ApplicationFiled: June 27, 2007Publication date: July 24, 2008Inventors: David P. Jacobus, Guy A. Schiehser, Hong-Ming Shieh, Norman P. Jensen, Jacek Terpinski
-
Patent number: 7393691Abstract: The method and apparatus rapidly separate drugs and their metabolites from saliva and, in a continuous sequence of steps, rapidly detect, identify and quantify them through surface-enhanced Raman spectroscopy.Type: GrantFiled: October 18, 2004Date of Patent: July 1, 2008Assignee: Real-Time Analyzers, Inc.Inventors: Stuart Farquharson, Alan D. Gift, Frank E. Inscore, Chetan S. Shende
-
Patent number: 7393692Abstract: The method and apparatus rapidly separate drugs and their metabolites from saliva and, in a continuous sequence of steps, rapidly detect, identify and quantify them through surface-enhanced Raman spectroscopy.Type: GrantFiled: April 5, 2005Date of Patent: July 1, 2008Assignee: Real-Time Analyzers, Inc.Inventors: Stuart Farquharson, Frank E. Inscore, Alan D. Gift, Chetan S. Shende
-
Publication number: 20080090301Abstract: The invention is a method to detect adulterated specimens submitted for substance abuse. It is concerned with testing a sample of the submitted urine, and in a parallel test analyze a sample of the submitted urine to which has been added known amount of the suspected substance. A control artificial urine with the same concentration of suspected substances as the added known amounts is analyzed in a third parallel test. If the measured amounts of the suspect drug is less than the additive amounts of the submitted urine plus the added know substances the specimen sample is suspect and subject to further consideration.Type: ApplicationFiled: October 13, 2006Publication date: April 17, 2008Inventor: Michael Sands Smith
-
Patent number: 7332345Abstract: A chemical sensing apparatus and method for the detection of sub parts-per-trillion concentrations of molecules in a sample by optimizing electron utilization in the formation of negative ions is provided. A variety of media may be sampled including air, seawater, dry sediment, or undersea sediment. An electrostatic mirror is used to reduce the kinetic energy of an electron beam to zero or near-zero kinetic energy.Type: GrantFiled: November 12, 2002Date of Patent: February 19, 2008Assignee: California Institute of TechnologyInventors: Murray R. Darrach, Ara Chutjian
-
Publication number: 20070224690Abstract: The subject invention provides a varenicline composition that comprises varenicline, or a pharmaceutically acceptable salt thereof, and an amount of a compound selected from one or more of several mononitro, monoamino, mixed aminonitro, diamino or dinitro intermediates, and the concentration of said compound is greater than 0 ppm and not greater than about 500 ppm, not greater than about 100 ppm or not greater than about 10 ppm. Methods for synthesizing and using such varenicline compositions are also provided.Type: ApplicationFiled: March 26, 2007Publication date: September 27, 2007Inventors: Frank R. Busch, Gregory J. Withbroe, Terry G. Sinay, Karen S. Bronk
-
Patent number: 7255835Abstract: Apparatus and method for acquiring an infrared spectrum of a sample having or suspected to have an amide I band, an amide II band, an amide III band, an amide A band, an OH stretching region or a combination thereof. A representative method includes providing a sample; providing an internal reflecting element (IRE) with a functionalized tip; contacting the sample with the IRE to form a sample-IRE interface; directing a beam of infrared (IR) radiation through the IRE under conditions such that the IR radiation interacts with the sample-IRE interface once; recording a reflectance profile over a range of preselected frequencies, whereby an infrared spectrum of the of a sample having or suspected of having an amide I band, an amide II band, an amide III band, an amide A band, an OH stretching region or a combination thereof, disposed in an aqueous solution is acquired.Type: GrantFiled: September 4, 2002Date of Patent: August 14, 2007Assignee: North Carolina State UniversityInventors: Stefan Franzen, Simon E. Lappi
-
Patent number: 7198955Abstract: A method is disclosed whereby the concentration of a blood substitute, such as cross-linked hemoglobin, in a serum or plasma specimen is rapidly and accurately identified and quantified. The method further takes the measured concentration of the blood substitute and uses it to correct for its effect, if any, on a measured analyte concentration, e.g., serum/plasma total protein. Further, the method allows for the determination of the concentration of true hemoglobin in the presence of blood substitutes. The method is carried out in respect of samples contained in a primary or secondary labelled tube, or a pipette tip used to dispense serum or plasma in a blood analyzer.Type: GrantFiled: October 16, 1997Date of Patent: April 3, 2007Assignee: NIR Diagnostics Inc.Inventors: James Samsoondar, Duncan MacIntyre